Targeted nonviral gene therapy in prostate cancer

Najla Altwaijry, Sukrut Somani, Christine Dufès

Research output: Contribution to journalArticle

12 Citations (Scopus)
21 Downloads (Pure)


Prostate cancer is the second most widespread cancer in men worldwide. Treatment choices are limited to prostatectomy, hormonal and radiotherapy that commonly have deleterious side effects and vary in their efficacy, depending on the stage of the disease. Among novel experimental strategies, gene therapy holds great promise for the treatment of prostate cancer. However, its use is currently limited by the lack of delivery systems able to selectively deliver the therapeutic genes to the tumors after intravenous administration without major drawbacks. To remediate to this problem, a wide range of non-viral delivery approaches have been developed to specifically deliver DNA-based therapeutic agents to their site of action. This review provides an overview of the various non-viral delivery strategies and gene therapy concepts used to deliver therapeutic DNA to prostate cancer cells, and focuses on the recent therapeutic advances being made so far.
Original languageEnglish
Pages (from-to)5753—5767
Number of pages15
JournalInternational Journal of Nanomedicine
Publication statusPublished - 25 Sep 2018


  • prostate cancer therapy
  • gene delivery
  • tumor targeting
  • nanomedicine

Fingerprint Dive into the research topics of 'Targeted nonviral gene therapy in prostate cancer'. Together they form a unique fingerprint.

  • Cite this